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Abstract In several countries, 3,4-methylenedioxymethamphet-
amine (MDMA) is currently the most abundant psychoactive
recreational drug. MDMA induces numerous neuropsychiatric
behaviors, serotonergic neuron degeneration, programmed death
of cultured cells, hyperthermia and occasional fatality. Using
gene expression analysis in MDMA-treated mice, we identi¢ed
changes in Q-amino butyric acid (GABA) transporters and syn-
aptotagmins I and IV. Additional experiments showed decreases
in mRNAs encoding septin and dystrophin. Although belonging
to di¡erent gene families, it is striking that these four protein
groups are implicated in neurotransmission of GABA, a major
inhibitory neurotransmitter involved in thermoregulation.
MDMA may control these genes in a combined fashion, assign-
ing GABA a pivotal role in MDMA activities.
, 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction: pro¢ling gene expression after MDMA
treatment
3,4-Methylenedioxymethamphetamine (MDMA) (also called
Ecstasy) enhances in the brain the release of the amine neuro-
transmitters, serotonin, noradrenaline and dopamine, and
generates multiple short- and long-term neuropsychiatric be-
haviors, including memory de¢cits (see [1,2] for recent re-
views). In animals, MDMA is neurotoxic to brain serotoner-
gic neurons, and it induces programmed cell death in cultured
human cells [3], cortical neurons [4] and liver cells [5]. It was
therefore of interest to investigate whether MDMA alters the
expression of certain genes in the brain. Initial studies showed
that MDMA alters the expression of serotonin and corticoid
receptors [6], as well as genes coding for Bcl-2 proteins, c-fos
and egr-1 (NGFI-A) [4,7,8]. More recently, Cadet and col-
leagues have used cDNA array analysis, and observed
MDMA-induced changes in expression of 28 genes associated
with diverse activities [9].
The ¢rst set of genes we identi¢ed as being a¡ected by
MDMA was the Q-amino butyric acid (GABA) transporter
(GAT) family; MDMA had a di¡erential e¡ect on expression
of three GAT isoforms ([10] and Table 1). The signi¢cance of
activation of mGAT1 and mGAT4 expression by MDMA,
along with no change in mGAT2 expression, was discussed
recently [11]. Involvement of GATs in GABA neurotransmis-
sion is readily explicable, as neuronal and glial GATs are the
major players in maintaining proper synaptic GABA levels
[12]. The increase in GAT expression and protein [10] is likely
to result in an enhanced GABA re-uptake and a lower extra-
cellular GABA level. This should re-modulate GAT expres-
sion, since GABA itself regulates the expression of GATs
[13,14]. It is worth noting, however, that expression of the
glial GABA transporter is also under the regulation of sero-
tonin [15]. The initial MDMA-induced release of serotonin
can therefore directly regulate the expression of GATs.
It was also found that MDMA altered the expression of
synaptotagmins I and IV, the e¡ect being in an opposite di-
rection for the two genes [16]. These two proteins belong to a
family of about a dozen members, having multiple functions
such as acting as immediate-early genes and controlling of
neurite outgrowth [17]. A major role of synaptotagmins is
the control of presynaptic vesicle tra⁄cking, docking and fu-
sion to the plasma membrane, and neurotransmitter secretion
[18,19]. Interestingly, synaptotagmins I and IV can form het-
erooligomers, and the ratio of the two proteins modulates
synaptic function [20]. It is hypothesized herein that the cross-
talk between synaptotagmins and GABA neurotransmission is
indirect, as follows: synaptotagmins bind to presynaptic plas-
ma membrane proteins such as syntaxin [21,22]. In a series of
studies Quick and associates have shown that syntaxin 1A
interacts with GAT1 [23] and regulates the transport rate of
GABA [24]. Moreover, later experiments from the same lab-
oratory con¢rmed that syntaxin 1A induces redistribution of
GAT, resulting in an enhanced GABA transport [25]. This
later work also showed that other presynaptic proteins, pos-
sibly synaptotagmins, are involved in controlling GAT1 activ-
ity. Taking into account the e¡ect of MDMA on the expres-
sion of two GATs and two synaptotagmins, and the central
role of GATs in GABA transport, it is tempting to conclude
that syntaxin 1A may act as a link between synaptotagmins
and the control of GABA transport. However, one cannot ex-
clude additional activities of these proteins in the MDMA-
treated brain, e.g. since MDMA induces neurodegeneration
of serotonergic ¢bers, synaptotagmins and syntaxin may par-
ticipate in membrane repair processes in the damaged neu-
rons, as they do in PC12 neurites [26] and squid and cray¢sh
axons [27].
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2. Recent ¢ndings
Using di¡erential display polymerase chain reaction (DD
PCR) analysis, it was found that MDMA decreased in the
midbrain the expression of two additional cDNAs of 421
and 498 nucleotides (Table 1). Sequencing these cDNAs dem-
onstrated that they encode septin and dystrophin, respectively.
Surprisingly, a series of recent studies conducted by a number
of laboratories point out that both septins and dystrophins
are associated in the brain with the GABA system. Septins are
cytoskeletal proteins with guanosine triphosphatase (GTPase)
activity, and they are involved in cytokinesis and secretion
[28]. Di¡erent members of the septin family have distinct
but overlapping distribution in various tissues and in the
brain. Septin 5, also called CDCrel-1, is predominantly ex-
pressed in the nervous system, and it is abundant in presyn-
aptic inhibitory GABAergic terminals [29]. Interestingly, in
several brain regions CDCrel-1 [30] as well as Nedd 5 (septin
2) interact with syntaxin. The crosstalk between synaptotag-
min, syntaxin, and septin proteins certainly needs further as-
sessment, yet it seems probable that they cooperate presynap-
tically to monitor GABA transport (Scheme 2).
Dystrophin is a major cytoskeletal component of muscles
but also expressed in the brain, colocalized postsynaptically
with GABAA receptor subunits [31]. Furthermore, this last
study showed that mutant mice lacking dystrophin (Mdx
mice) have an altered clustering and stabilization of GABAA
receptor subunits in several brain regions. Experiments with
hippocampal slices from Mdx mice displayed abnormally en-
hanced synaptic plasticity, which was inhibited by bicuculline,
Table 1
Summary of MDMA e¡ect on expression of genes associated with GABA neurotransmission










mGAT1 298a increase increase increase increase 6 3p25.3
mGAT4 (hGAT-3) ^ increase increase increase increase 6 3p25.3
Synaptotagmin I ^ UL UL increase increase 10 12q21.2
Synaptotagmin IV 356b decrease decrease decrease decrease 18 18q12.3
Septinc 421 UL decrease NT NT 1/16 2q37.3/22q11.21
Dystrophind 498 UL decrease NT NT X/9 Xp21.2/3p21
UL, undetectable level; NT, not tested.
aDetails of the DD PCR, RT-PCR and real-time PCR methods, and the data regarding MDMA e¡ect on mGAT1, mGAT2 and mGAT4 ex-
pression in the brain were reported before [10]. mGAT4 is a homolog of rGAT-3 and hGAT-3.
bThe data regarding synaptotagmins I and IV were reported before [16].
cChromosomal localizations of septin 2 (Nedd 5) and septin 5 (CDCrel-1) are shown.
dChromosomal localizations of dystrophin and dystrophin-associated glycoprotein 1 (DAG1=dystroglycan 1) are shown. For comparison, the
chromosomal locations of SERT and DAT are mouse 11 and 13 and human 17q11.2 and 5p15.33, respectively.
Scheme 1. The three major neuronal systems involved in MDMA activity. The serotonergic, dopaminergic, and GABAergic neurons are shown
in a schematic form. All or part of these systems, as well as other neuronal pathways not shown (such as the noradrenergic and glutamatergic)
may contribute to the MDMA-induced altered gene expression pro¢le as described over the years [1,2,4^10,16]. SERT, 5-HT transporter.
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a selective GABAA receptor antagonist [32]. Dystrophin also
interacts with the tubulin-binding protein gephrin, an impor-
tant player in the assembly of the GABAergic postsynaptic
membrane [33]. Knockout mice devoid of gephrin are de¢-
cient in GABAA receptor subunits, but they show a normal
distribution of another (excitatory) postsynaptic receptor [34].
Finally, a complex of dystrophin and a glycoprotein (dystro-
glycan) was observed in a subset of inhibitory synapses, colo-
calized with GABAA receptors [35].
3. Summary and conclusions
Thiriet et al. [9] took a wide-ranging approach to unravel-
ling MDMA e¡ects on the brain by using the cDNA array
method, and analyzed the temporal changes in gene expres-
sion in the rat cortex. They found changes in genes encoding
proteins active in nine functional systems, including signal
transduction (receptors, G-proteins, kinases), transcription
factors, cytoskeleton/matrix proteins, proteins reacting to oxi-
dative stress, and metabolism. This study opened new avenues
in elucidating the repertoire of MDMA activities, and also
con¢rmed some early ¢ndings, using more conventional meth-
ods [6^8]. Likewise, the observation that MDMA decreased
expression of Bcl-2 in the cortex [9] is in line with experiments
with cultured cells, indicating activation of programmed cell
death by MDMA [3^5]. Yet, there are many open questions
as to the speci¢c neuronal system responsible for each altered
gene (see Scheme 1), initial versus late e¡ects resulting from
adaptive processes, and the causal relationship between a cer-
tain gene and some drug-induced neuropsychiatric behavior(s)
or memory loss.
In mice, we found that MDMA altered the expression of
the GABA transporters mGAT1 and mGAT4, synaptotag-
mins I and IV, septin and dystrophin. A common feature of
these proteins, as reported by a number of laboratories, is that
all of them are associated with GABA neurotransmission. It is
noteworthy that they belong to four di¡erent gene families,
and lack any obvious relation in chromosomal localization in
mice or human (Table 1). Nevertheless these proteins were
found in GABAergic synapses, either presynaptically, thus
able to modulate GABA release or re-uptake, or postsynap-
tically, accessible for regulation of GABAA receptors (Scheme
2). To what extent is this observation relevant to the wide
repertoire of MDMA e¡ects in vivo, which comprises seroto-
nergic neuron degeneration, psychostimulation, hyperthermia
and occasional death? Studies by Yamamoto and associates
[36] have shown that activation of serotonin receptors by se-
rotonin after treatment with MDMA results in a diminished
e¥ux of GABA, followed with an enhanced activity of dopa-
minergic neurons and dopamine release. Ample evidence sug-
gests that activation of the dopamine system is central to
MDMA-induced psychoactivation, oxidative stress, and sero-
tonergic degeneration ([1,2] and references included). Yet,
GABAergic neurons are key players in MDMA-induced loss
of serotonergic axons [37,38]. The crosstalk between the sero-
tonin, dopamine and GABA systems is therefore crucial to the
multiple behavioral and gene expression changes induced by
the drug (illustrated in Scheme 1). Focusing on the role of
GABA, it is worth noting the early work of Green and asso-
ciates that drugs enhancing GABAergic neurons attenuate the
later depletion in serotonin, which accompanies serotonergic
nerve terminal degeneration [39,40]. Later studies con¢rmed
that pentobarbitone [37], acting on ion channels associated
with GABA receptors, and the GABA agonist baclofen [41]
diminish MDMA-induced neurotoxicity. Furthermore, recent
experiments have shown that GAT inhibitors reduce MDMA
toxicity in mice [10]. By and large, the recognition that
MDMA alters the expression of several genes involved in
GABA neurotransmission emphasizes the essential role of
GABA in MDMA activity in the brain. GABA plays a role
in thermoregulation [42,43], and MDMA-induced fatality in
drug users is coupled with severe hyperthermia [1,2]. Un-
doubtedly more rigorous assessment of the multiple molecular
pathways that participate in controlling the expression of the
genes involved in GABA neurotransmission should provide
important insights in the mechanism of action of MDMA
and similar psychostimulants. GABA neurotransmission at
pre- or postsynaptic sites could also serve as a useful drug
Scheme 2. Hypothetical synaptic location of proteins involved in MDMA-induced GABA neurotransmission. This illustration is based on our
recent ¢ndings [10,16] and studies conducted by several other laboratories [17^25,28^35].
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target to alleviate some of the deleterious e¡ects of MDMA
and similar psychoactive drugs, including sporadic fatality
among drug users.
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